1. Medtech Insight
  2. >>Business

Earnings Winners And Losers: BSX, BCR, NUVA, NVCR

 
• By Reed Miller

Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.

Boston Scientific Corp.(BSX): Magnetic resonance imaging-compatible implantable devices helped Boston Scientific avoid the fate of its rival St. Jude Medical Inc., which has struggled to grow its cardiac rhythm management revenues without MR-compatible devices in most markets. Boston Scientific’s CRM division revenues grew 5% on an operational basis in the second quarter of 2016, helped by the US FDA approval of the ImageReady MR-conditional pacing system, including the Ingevity MRI pacing leads, and the CE mark of the Emblem MRI subcutaneous ICD system, also announced in May. (Also see "APPROVALS ANALYSIS: Big Month For Cardio Devices, But Down Overall" - Medtech Insight, 6 May, 2016.) However, Wells Fargo analyst Larry Biegelsen points out in a July 29 note that “[CRM] growth continued to lag the other businesses [in BSX] due to US product gaps on the high-voltage side.”

The company’s cardiovascular division grew 13% during the quarter, helped by 12% growth of the interventional cardiology business led by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ellipsis Raises $45M To Expand AI Care Manager Across Health Systems

 
• By Marion Webb

Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 
• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.